TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Oncology
Lynch syndrome for the gynaecologist
Key Statistics
- 1:278–440 — Population prevalence of Lynch syndrome
- ~3% — Endometrial cancers caused by Lynch syndrome
- ≤56.7% — Lifetime EC risk (MSH2, by age 70)
Don't-miss facts
-
LS = autosomal dominant MMR gene defect (MLH1, MSH2, MSH6, PMS2, ±EpCAM); prevalence 1 in 278–440, ≤95% unaware
-
Gene-specific EC risk by 70y: MLH1 42.7%, MSH2 56.7%, MSH6 46.2%, PMS2 26.4% – MSH6 EC risk high despite low CRC risk
-
NICE: universal LS screening for all endometrial cancers where resources allow
-
Tumour testing (IHC/MSI) needs no explicit consent; germline testing is definitive and always needs informed consent
-
Risk-reducing hysterectomy+BSO timing: MLH1/MSH2 35y, MSH6 40y, PMS2 50y
-
Pembrolizumab licensed for MSI-H/MMR-deficient tumours of any primary site
-
PREMM5: >5% → refer genetics; >2.5% → tumour testing
-
LS surveillance evidence weak; LS-EC 10-yr survival ≥90%; no proven OC surveillance benefit
Testing pathway at a glance
Tumour triage (IHC ± MSI ± MLH1 methylation) – no consent needed Germline NGS – definitive, always needs informed consent
Abbreviation Key
- LS — Lynch syndrome
- PGT — pre-implantation genetic testing
- MMR — DNA mismatch repair
- HFEA — Human Fertilisation and Embryology Authority
- MLH1/MSH2/MSH6/PMS2 — mismatch repair genes
- BSO — bilateral salpingo-oophorectomy
- EpCAM — epithelial cell adhesion molecule
- EC/OC — endometrial cancer / ovarian cancer
- IHC — immunohistochemistry
- NICE — National Institute for Health and Care Excellence
- MSI — microsatellite instability
- PD-1/PD-L1 — programmed cell death protein 1 / its ligand
- MSI-H/L/MSS — MSI-high / MSI-low / microsatellite stable
- FDA — US Food and Drug Administration
- VUS — variant of unknown significance
- UKFOCS — United Kingdom Familial Ovarian Cancer Screening Study
- NGS — next-generation sequencing
- CI — confidence interval
Source: Ryan N et al. Lynch syndrome for the gynaecologist. The Obstetrician & Gynaecologist 2021;23:9–20. doi:10.1111/tog.12706
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).